Key facts
- This page summarizes Daniel J. Levangie's Form 4 filing for Renalytix plc (RNLXY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Nov 2023, 16:28.
Daniel J. Levangie - 20 Nov 2023 Form 4 Insider Report for Renalytix plc (RNLXY)
- Reporting relationship
- Director
- Issuer ticker
- RNLXY
- Reported as of
- 20 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Nov 2023, 16:28:57 UTC
- Prior SEC filing
- 03 Jul 2023
- Next SEC filing
- 04 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Katie Kazem, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel J. Levangie filed Form 4 for Renalytix plc (RNLXY) on 22 Nov 2023.
Change
- Previous filing in this sequence was filed on 03 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNLX
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +95,000
- Change %
- Price
- $0.000000
- Shares after
- 95,000
- Date
- 20 Nov 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 95,000
- Exercise price
- $0.3040
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).
Footnote F2
One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service.